Nan Shan Life Insurance Co. Ltd. reduced its position in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 71.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,216 shares of the medical instruments supplier's stock after selling 78,651 shares during the quarter. Nan Shan Life Insurance Co. Ltd.'s holdings in West Pharmaceutical Services were worth $11,207,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Addison Advisors LLC purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at $28,000. Avalon Trust Co bought a new position in West Pharmaceutical Services in the 2nd quarter worth about $28,000. Elyxium Wealth LLC bought a new position in West Pharmaceutical Services in the 4th quarter worth about $25,000. Bayban purchased a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at about $27,000. Finally, DV Equities LLC bought a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at about $28,000. Institutional investors own 93.90% of the company's stock.
Wall Street Analysts Forecast Growth
WST has been the topic of a number of recent analyst reports. Morgan Stanley raised their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an "equal weight" rating in a research note on Thursday, July 9th. Wolfe Research started coverage on shares of West Pharmaceutical Services in a research report on Monday, June 1st. They issued an "outperform" rating and a $375.00 target price for the company. BNP Paribas Exane started coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They set an "outperform" rating and a $447.00 price target on the stock. Barclays upgraded West Pharmaceutical Services from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $310.00 to $400.00 in a research report on Tuesday, June 9th. Finally, KeyCorp upped their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an "overweight" rating in a research note on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, West Pharmaceutical Services currently has an average rating of "Moderate Buy" and a consensus price target of $368.08.
Check Out Our Latest Report on West Pharmaceutical Services
West Pharmaceutical Services Price Performance
WST opened at $339.04 on Wednesday. The stock's 50 day simple moving average is $350.85 and its 200 day simple moving average is $305.33. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00. The firm has a market cap of $23.86 billion, a price-to-earnings ratio of 43.41, a PEG ratio of 2.39 and a beta of 1.14.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million for the quarter, compared to analysts' expectations of $839.98 million. During the same quarter last year, the business earned $1.84 earnings per share. The business's revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.
West Pharmaceutical Services Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a $0.22 dividend. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services's payout ratio is presently 11.27%.
West Pharmaceutical Services Company Profile
(
Free Report)
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
